ICCC vs PEAK
ImmuCell Corporation (ICCC) versus PEAK (PEAK) — a side-by-side from cached financials, not a winner call.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
PEAK (PEAK) common stock.
Latest reported ICCC revenue for 2024-12-31 was $26.5M. Net income was -$2.2M. Revenue was up 51.6% from 2023-12-31 to 2024-12-31. ICCC currently screens at market cap $58.9M.
PEAK does not have a complete income-statement cache yet.
ICCC currently screens at market cap $58.9M.
Not investment advice. Open the ICCC and PEAK stock pages for the full models.
Not investment advice.